Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03872128 · ClinicalTrials.gov registry record · Phase 1

The Role of Neuroactive Steroids in Stress, Alcohol Craving and Alcohol Use in Alcohol Use Disorders

A Phase 1 study of Alcohol Use Disorder, sponsored by Yale University.

Completed
Registry status
Phase 1
Development phase
91
Enrollment target
2
Study locations

NCT03872128: Completed Phase 1 study of Alcohol Use Disorder, sponsored by Yale University.

NCT03872128 is a Phase 1 study of Alcohol Use Disorder that has completed, run by Yale University. The registered enrollment target is 91 participants, below the 328-participant average among 184 other Alcohol Use Disorder trials with a reported enrollment target (72% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03872128, a Phase 1 study of Alcohol Use Disorder, has completed, sponsored by Yale University.

COMPLETED
Registry status
Phase 1
Development phase
91 participants
Enrollment target
2
Study locations

Study Summary

To use pregnenolone (PREG; 300; 500mg) daily versus placebo (PLA) as a probe to assess the role of neuroactive steroids in individuals with alcohol use disorder (AUD).

Primary Outcome

The mean percent drinking days as assessed by self report on daily smartphone monitoring and corroborated by the Substance Use Calendar over the 8 week period.

Conditions Studied

Alcohol Use Disorder

Interventions

  • DRUG Placebo
  • DRUG Pregnenolone300
  • DRUG Pregnenolone500

Study Locations (2)

Connecticut

  • The Yale Stress Center: Yale University - New Haven
  • Yale Stress Center - New Haven

Trial Details

FieldValue
Enrollment Target 91 participants
Start Date 2018-09-27
Est. Completion 2023-08-01
Phase Phase 1
Yale University

1,492 total trials

What the finished NCT03872128 record still lists

NCT03872128 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 91 participants, a relatively small participant target, below the 328-participant average among 184 other Alcohol Use Disorder trials with a reported enrollment target (72% lower).

The record links to 1 condition, with Alcohol Use Disorder appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.

NCT03872128 reports a single indexed study location in Connecticut.

Frequently Asked Questions

What is clinical trial NCT03872128 about?

NCT03872128 is a clinical study titled "The Role of Neuroactive Steroids in Stress, Alcohol Craving and Alcohol Use in Alcohol Use Disorders". To use pregnenolone (PREG; 300; 500mg) daily versus placebo (PLA) as a probe to assess the role of neuroactive steroids in individuals with alcohol use disorder (AUD).

What is the current status of trial NCT03872128?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 91 participants. The study started on 2018-09-27. Estimated completion is 2023-08-01.

What conditions does trial NCT03872128 study?

This clinical trial studies the following conditions: Alcohol Use Disorder.

What interventions are being tested in trial NCT03872128?

The interventions under investigation include: Placebo (DRUG), Pregnenolone300 (DRUG), Pregnenolone500 (DRUG).

Who is sponsoring clinical trial NCT03872128?

This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03872128 being conducted?

This trial has 2 study locations across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Alcohol Use Disorder

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03872128's enrollment target sits among peer trials

91 88th of 184 higher than 96 of 184 other Alcohol Use Disorder trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Alcohol Use Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02671448 · 91 participants · NA

    Pilot Trial of Homebound Stem Cell Transplantation

  • NCT04835857 · 91 participants

    Comparison of Cuff-Less Wrist Wearable Blood Pressure Device to Cuff Based Blood Pressure Measuring Devices

  • NCT05184842 · 91 participants · Phase 2

    Metabolically Optimized, Non-cytotoxic Low Dose Weekly Decitabine/Venetoclax in MDS and AML

  • NCT05685173 · 91 participants · Phase 1

    A Trial to Study if REGN5837 in Combination With Odronextamab is Safe for Adult Participants With Aggressive B-cell Non-Hodgkin Lymphomas

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT03872128, the US trial registry maintained by the National Library of Medicine. NCT03872128 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.